Awardee OrganizationUNIVERSITY OF MIAMI SCHOOL OF MEDICINE
Description
Abstract Text
The broad objective of this proposal is to demonstrate that the collateral
vascular response to experimental thrombotic stroke of the middle cerebral
artery (MCA) territory in the rat can be controlled by stimulating or
inhibiting the synthesis of endothelial-derived relaxing factor (EDRF). If
this assertion is correct, the volume of MCA territory infarct should be
maximal and consistent if EDRF synthesis is suppressed (specific aim 1),
and minimized (but likely inconsistent) if EDRF synthesis is enhanced
(specific aim 2). Observation of infarct consistency in a normally well-
collateralized but not carotid artery-ligated (Wistar) rat would be
unprecedented, and important for evaluation of anti-ischemic drugs.
Observation of infarct mitigation by EDRF stimulation would suggest that
EDRF-induced activation of collateral circulation be used clinically to
reduce infarct volume, even if the MCA (or other intracranial artery)
remains occluded. In specific aim 3, infarct volume and consistency will
be monitored in rats initially subjected to EDRF inhibition and MCA
thrombosis (for time periods of up to 3 hours) after complete restoration
of anterograde flow by lysis of the MCA thrombi together with EDRF
enhancement. Under these apparently optimal reflow conditions, however,
the theoretical possibility of reperfusion injury should also be maximized.
This paradox will be evaluated histopathologically and biochemically (in
terms of peroxidized lipid conjugated dienes) for this aim, and for the
first two also (specific aim 4), thus facilitating assessment of the long-
hypothesized contribution of (presumably) oxygen radical-mediated lipid
peroxidation to the initiation of reperfusion injury.
In our methodology the MCA thrombi are formed in specific arterial segments
in response to photochemically induced endothelial injury mediated by an
intravenously injected dye in conjunction with a focussed laser beam of the
appropriate wavelength. Thrombi formed in response to rose bengal
injection and irradiation with an argon/dye laser beam at 562 nm can be
lysed by hementin (from the leech Haementeria ghilianii). Inhibition of
EDRF synthesis is achieved by intravenous infusion of NG-nitro-1-arginine
methyl ester hydrochloride (1-NAME), while enhancement of EDRF synthesis is
achieved with infusion of either 1-arginine hydrochloride (ARG) or
N(alpha)-benzoyl-l-arginine ethyl ester hydrochloride (BAEE). Conjugated
diene content is analyzed spectroscopically in total lipid extracts from
small (less than 1 mg) cortical punch biopsies. Under the conditions of
aim 3 the detection of lipid peroxidation in time during reperfusion should
be much more consistent compared to previous efforts.
National Institute of Neurological Disorders and Stroke
CFDA Code
854
DUNS Number
052780918
UEI
F8THLJQSAF93
Project Start Date
01-August-1985
Project End Date
31-December-1999
Budget Start Date
01-March-1998
Budget End Date
31-December-1999
Project Funding Information for 1998
Total Funding
$258,053
Direct Costs
$168,662
Indirect Costs
$89,391
Year
Funding IC
FY Total Cost by IC
1998
National Institute of Neurological Disorders and Stroke
$258,053
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01NS023244-13
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01NS023244-13
Patents
No Patents information available for 5R01NS023244-13
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01NS023244-13
Clinical Studies
No Clinical Studies information available for 5R01NS023244-13
News and More
Related News Releases
No news release information available for 5R01NS023244-13
History
No Historical information available for 5R01NS023244-13
Similar Projects
No Similar Projects information available for 5R01NS023244-13